Primary updates to the guidance includes the composition of the 2020-2021 flu vaccines and the recent licensures of 2 new influenza vaccines.
The Advisory Committee on Immunization Practices (ACIP) updated its seasonal flu vaccine guidance for the 2020-2021 influenza season.
With flu season approaching, pharmacies are gearing up for a busy season as the coronavirus disease 2019 (COVID-19) continues to circulate. Prevention of and reduction in the severity of influenza illnesses and reduction of outpatient illnesses, hospitalizations, and intensive care unit admission is especially important to alleviate stress on the US health care system during the pandemic.
According to ACIP, primary updates and changes to the recommendations include the vaccine virus composition for 2020-2021 US seasonal influenza vaccines and recent regulatory actions, including 2 new influenza vaccine licensures.
In general, routine annual influenza vaccination of all individuals aged 6 months and older who do not have contraindications continues to be recommended. No preferential recommendations is made for 1 influenza vaccine product over another for individuals for whom more than 1 licensed, recommended, and appropriate product is available.
The composition of the 2020-2021 US influenza vaccine includes updates to the influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B/Victoria lineage components. The following influenza vaccines will be available for this season:
Two new influenza vaccine licensures are described in the updated guidance:
Additional changes include:
Read the full report for more information.
Reference
Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices–United States, 2020-21 influenza season. Morbidity and Mortality Weekly Report. 2020. Doi: http://dx.doi.org/10.15585/mmwr.rr6908a1external icon
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.